Wei Zheng

List of Publications by Year
in descending order

290 papers	15,427 citations	19657 61 h-index	26613 107 g-index
295 all docs	295 docs citations	295 times ranked	22847 citing authors

#	ARTICLE	IF	CITATIONS
1	Continuous Encoding for Overlapping Community Detection in Attributed Network. IEEE Transactions on Cybernetics, 2023, 53, 5469-5482.	9.5	4
2	Data Quality Matters: A Case Study on Data Label Correctness for Security Bug Report Prediction. IEEE Transactions on Software Engineering, 2022, 48, 2541-2556.	5.6	71
3	SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening. ACS Pharmacology and Translational Science, 2022, 5, 8-19.	4.9	5
4	Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors. MBio, 2022, 13, e0323821.	4.1	11
5	A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry. SLAS Discovery, 2022, 27, 86-94.	2.7	16
6	Domain knowledge-based security bug reports prediction. Knowledge-Based Systems, 2022, 241, 108293.	7.1	29
7	iPS-derived neural stem cells for disease modeling and evaluation of therapeutics for mucopolysaccharidosis type II. Experimental Cell Research, 2022, 412, 113007.	2.6	5
8	c-Abl Activation Linked to Autophagy-Lysosomal Dysfunction Contributes to Neurological Impairment in Niemann-Pick Type A Disease. Frontiers in Cell and Developmental Biology, 2022, 10, 844297.	3.7	9
9	Efficient Identification of Anti-SARS-CoV-2 Compounds Using Chemical Structure- and Biological Activity-Based Modeling. Journal of Medicinal Chemistry, 2022, 65, 4590-4599.	6.4	15
10	Repurposing drugs as COVID-19 therapies: A toxicity evaluation. Drug Discovery Today, 2022, 27, 1983-1993.	6.4	16
11	Mitoxantrone modulates a heparan sulfate-spike complex to inhibit SARS-CoV-2 infection. Scientific Reports, 2022, 12, 6294.	3.3	8
12	Graph Convolutional Network-Based Screening Strategy for Rapid Identification of SARS-CoV-2 Cell-Entry Inhibitors. Journal of Chemical Information and Modeling, 2022, 62, 1988-1997.	5.4	1
13	LOMETS3: integrating deep learning and profile alignment for advanced protein template recognition and function annotation. Nucleic Acids Research, 2022, 50, W454-W464.	14.5	17
14	DEMO2: Assemble multi-domain protein structures by coupling analogous template alignments with deep-learning inter-domain restraint prediction. Nucleic Acids Research, 2022, 50, W235-W245.	14.5	15
15	Progressive assembly of multi-domain protein structures from cryo-EM density maps. Nature Computational Science, 2022, 2, 265-275.	8.0	25
16	Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19. ACS Infectious Diseases, 2022, 8, 1191-1203.	3.8	4
17	Discovery and Optimization of Pyrrolopyrimidine Derivatives as Selective Disruptors of the Perinucleolar Compartment, a Marker of Tumor Progression toward Metastasis. Journal of Medicinal Chemistry, 2022, 65, 8303-8331.	6.4	4
18	Effects of SARSâ€CoVâ€2 mutations on protein structures and intraviral proteinâ€"protein interactions. Journal of Medical Virology, 2021, 93, 2132-2140.	5.0	85

#	Article	IF	Citations
19	The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalizing Small Molecules. ACS Infectious Diseases, 2021, 7, 1389-1408.	3.8	74
20	Structural interaction between DISC1 and ATF4 underlying transcriptional and synaptic dysregulation in an iPSC model of mental disorders. Molecular Psychiatry, 2021, 26, 1346-1360.	7.9	22
21	Functions of Essential Genes and a Scale-Free Protein Interaction Network Revealed by Structure-Based Function and Interaction Prediction for a Minimal Genome. Journal of Proteome Research, 2021, 20, 1178-1189.	3.7	23
22	An Integrated Systems Biology Approach Identifies the Proteasome as A Critical Host Machinery for ZIKV and DENV Replication. Genomics, Proteomics and Bioinformatics, 2021, 19, 108-122.	6.9	7
23	Biological activity-based modeling identifies antiviral leads against SARS-CoV-2. Nature Biotechnology, 2021, 39, 747-753.	17.5	38
24	Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics. Scientific Reports, 2021, 11, 6725.	3.3	25
25	Induction of interferon signaling and allograft inflammatory factor 1 in macrophages in a mouse model of breast cancer metastases. Wellcome Open Research, 2021, 6, 52.	1.8	5
26	Identification of Antifungal Compounds against Multidrug-Resistant Candida auris Utilizing a High-Throughput Drug-Repurposing Screen. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	19
27	Deducing high-accuracy protein contact-maps from a triplet of coevolutionary matrices through deep residual convolutional networks. PLoS Computational Biology, 2021, 17, e1008865.	3.2	70
28	SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance. Cell Death and Disease, 2021, 12, 341.	6.3	13
29	Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva. JCI Insight, 2021, 6, .	5.0	29
30	mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease. Nature Communications, 2021, 12, 3090.	12.8	35
31	Generation of an induced pluripotent stem cell line (TRNDi030-A) from a patient with Farber disease carrying a homozygous p. Y36C (c. 107 A>G) mutation in ASAH1. Stem Cell Research, 2021, 53, 102387.	0.7	2
32	Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection. Bioorganic and Medicinal Chemistry Letters, 2021, 40, 127906.	2.2	15
33	Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development. Journal of Pharmacology and Experimental Therapeutics, 2021, 378, 166-172.	2.5	19
34	Improving high-impact bug report prediction with combination of interactive machine learning and active learning. Information and Software Technology, 2021, 133, 106530.	4.4	73
35	High‐throughput screening assays for SARS‐CoV‐2 drug development: Current status and future directions. Drug Discovery Today, 2021, 26, 2439-2444.	6.4	21
36	Generation of Alagille syndrome derived induced pluripotent stem cell line carrying heterozygous mutation in the JAGGED-1 gene at splicing site (Chr20: 10,629,709C>A) before exon 11. Stem Cell Research, 2021, 53, 102366.	0.7	2

#	Article	IF	Citations
37	Mechanism for DPY30 and ASH2L intrinsically disordered regions to modulate the MLL/SET1 activity on chromatin. Nature Communications, 2021, 12, 2953.	12.8	21
38	Drug combination therapy for emerging viral diseases. Drug Discovery Today, 2021, 26, 2367-2376.	6.4	65
39	Induction of interferon signaling and allograft inflammatory factor 1 in macrophages in a mouse model of breast cancer metastases. Wellcome Open Research, 2021, 6, 52.	1.8	6
40	Enrichment of NPC1-deficient cells with the lipid LBPA stimulates autophagy, improves lysosomal function, and reduces cholesterol storage. Journal of Biological Chemistry, 2021, 297, 100813.	3.4	29
41	Generation of an induced pluripotent stem cell line (TRNDi031-A) from a patient with Alagille syndrome type 1 carrying a heterozygous p. C312X (c. 936ÂTÂ>ÂA) mutation in JAGGED-1. Stem Cell Research, 2021, 54, 102447.	0.7	1
42	Discovery of Small Molecule Entry Inhibitors Targeting the Fusion Peptide of SARS-CoV-2 Spike Protein. ACS Medicinal Chemistry Letters, 2021, 12, 1267-1274.	2.8	16
43	Folding non-homologous proteins by coupling deep-learning contact maps with I-TASSER assembly simulations. Cell Reports Methods, 2021, 1, 100014.	2.9	272
44	Generation of an induced pluripotent stem cell line (TRNDi012-B) from Fibrodysplasia Ossificans Progressiva (FOP) patient carrying a heterozygous mutation c. 617GÂ>ÂA in the ACVR1 gene. Stem Cell Research, 2021, 54, 102424.	0.7	0
45	An induced pluripotent stem cell line (NCATS-CL9075) from a patient carrying compound heterozygote mutations, p.R390P and p.L318P, in the NGLY1 gene. Stem Cell Research, 2021, 54, 102400.	0.7	0
46	Therapeutics Development for Alagille Syndrome. Frontiers in Pharmacology, 2021, 12, 704586.	3.5	7
47	Protein structure prediction using deep learning distance and hydrogen€bonding restraints in <scp>CASP14</scp>. Proteins: Structure, Function and Bioinformatics, 2021, 89, 1734-1751.	2.6	53
48	Improving fragment-based ab initio protein structure assembly using low-accuracy contact-map predictions. Nature Communications, 2021, 12, 5011.	12.8	44
49	High-throughput protein modification quantitation analysis using intact protein MRM and its application on hENGase inhibitor screening. Talanta, 2021, 231, 122384.	5.5	3
50	Protein inter€residue contact and distance prediction by coupling complementary coevolution features with deep residual networks in <scp>CASP14</scp>. Proteins: Structure, Function and Bioinformatics, 2021, 89, 1911-1921.	2.6	23
51	Protein structural features predict responsiveness to pharmacological chaperone treatment for three lysosomal storage disorders. PLoS Computational Biology, 2021, 17, e1009370.	3.2	4
52	Hybrid <i>In Silico</i> Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants. ACS Pharmacology and Translational Science, 2021, 4, 1675-1688.	4.9	6
53	Generation of two gene corrected human isogenic iPSC lines (NCATS-CL6104 and NCATS-CL6105) from a patient line (NCATS-CL6103) carrying a homozygous p.R401X mutation in the NGLY1 gene using CRISPR/Cas9. Stem Cell Research, 2021, 56, 102554.	0.7	1
54	Disease modeling for Mucopolysaccharidosis type IIIB using patient derived induced pluripotent stem cells. Experimental Cell Research, 2021, 407, 112785.	2.6	3

#	Article	IF	Citations
55	A Comparative Study of Class Rebalancing Methods for Security Bug Report Classification. IEEE Transactions on Reliability, 2021, 70, 1658-1670.	4.6	65
56	Modeling CNS Involvement in Pompe Disease Using Neural Stem Cells Generated from Patient-Derived Induced Pluripotent Stem Cells. Cells, 2021, 10, 8.	4.1	13
57	Decoding the link of microbiome niches with homologous sequences enables accurately targeted protein structure prediction. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	12
58	Automatically Identifying Bug Reports with Tactical Vulnerabilities by Deep Feature Learning. , 2021, , .		1
59	Discovery and characterization of potent Andâ€1 inhibitors for cancer treatment. Clinical and Translational Medicine, 2021, 11, e627.	4.0	7
60	DeepMSA: constructing deep multiple sequence alignment to improve contact prediction and fold-recognition for distant-homology proteins. Bioinformatics, 2020, 36, 2105-2112.	4.1	147
61	SSIPe: accurately estimating proteinâ€"protein binding affinity change upon mutations using evolutionary profiles in combination with an optimized physical energy function. Bioinformatics, 2020, 36, 2429-2437.	4.1	42
62	CVE-assisted large-scale security bug report dataset construction method. Journal of Systems and Software, 2020, 160, 110456.	4.5	24
63	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. Antiviral Research, 2020, 173, 104667.	4.1	11
64	Four induced pluripotent stem cell lines (TRNDi021-C, TRNDi023-D, TRNDi024-D and TRNDi025-A) generated from fibroblasts of four healthy individuals. Stem Cell Research, 2020, 49, 102011.	0.7	2
65	Development of a High-Throughput Homogeneous AlphaLISA Drug Screening Assay for the Detection of SARS-CoV-2 Nucleocapsid. ACS Pharmacology and Translational Science, 2020, 3, 1233-1241.	4.9	10
66	RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery. SLAS Discovery, 2020, 25, 1141-1151.	2.7	131
67	Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro. Cell Discovery, 2020, 6, 80.	6.7	172
68	Carbon Dots for Efficient Small Interfering RNA Delivery and Gene Silencing in Plants. Plant Physiology, 2020, 184, 647-657.	4.8	107
69	Drug Discovery Strategies for SARS-CoV-2. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 127-138.	2.5	83
70	Pharmacological clearance of misfolded rhodopsin for the treatment of <i>RHO</i> â€associated retinitis pigmentosa. FASEB Journal, 2020, 34, 10146-10167.	0.5	10
71	Human recombinant lysosomal <scp>Î²â€Hexosaminidases</scp> produced in <scp><i>Pichia pastoris</i></scp> efficiently reduced lipid accumulation in <scp>Tayâ€Sachs</scp> fibroblasts. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2020, 184, 885-895.	1.6	7
72	Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles. ACS Pharmacology and Translational Science, 2020, 3, 1165-1175.	4.9	94

#	Article	IF	Citations
73	Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening. ACS Pharmacology and Translational Science, 2020, 3, 1008-1016.	4.9	162
74	Cell-Based No-Wash Fluorescence Assays for Compound Screens Using a Fluorescence Cytometry Plate Reader. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 500-511.	2.5	1
75	Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium. Cell Stem Cell, 2020, 27, 937-950.e9.	11.1	314
76	Torin 2 Derivative, NCATS-SM3710, Has Potent Multistage Antimalarial Activity through Inhibition of *P. falciparum* Phosphatidylinositol 4-Kinase (*Pf* PI4KIIIβ). ACS Pharmacology and Translational Science, 2020, 3, 948-964.	4.9	19
77	Zika Virus-Induced Neuronal Apoptosis via Increased Mitochondrial Fragmentation. Frontiers in Microbiology, 2020, 11, 598203.	3.5	27
78	Landscape of variable domain of heavy-chain-only antibody repertoire from alpaca. Immunology, 2020, 161, 53-65.	4.4	17
79	Protein Structure and Sequence Reanalysis of 2019-nCoV Genome Refutes Snakes as Its Intermediate Host and the Unique Similarity between Its Spike Protein Insertions and HIV-1. Journal of Proteome Research, 2020, 19, 1351-1360.	3.7	242
80	Generation and characterization of four Chediak-Higashi Syndrome (CHS) induced pluripotent stem cell (iPSC) lines. Stem Cell Research, 2020, 47, 101883.	0.7	5
81	Impact of mRNA chemistry and manufacturing process on innate immune activation. Science Advances, 2020, 6, eaaz6893.	10.3	195
82	Invalid bug reports complicate the software aging situation. Software Quality Journal, 2020, 28, 195-220.	2.2	15
83	FUpred: detecting protein domains through deep-learning-based contact map prediction. Bioinformatics, 2020, 36, 3749-3757.	4.1	44
84	Two-Level Protein Methylation Prediction using structure model-based features. Scientific Reports, 2020, 10, 6008.	3.3	7
85	The Human DNA Mismatch Repair Protein MSH3 Contains Nuclear Localization and Export Signals That Enable Nuclear-Cytosolic Shuttling in Response to Inflammation. Molecular and Cellular Biology, 2020, 40, .	2.3	17
86	Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2. Frontiers in Pharmacology, 2020, 11, 592737.	3.5	69
87	CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduction and Targeted Therapy, 2020, 5, 298.	17.1	225
88	Advancing precision medicine with personalized drug screening. Drug Discovery Today, 2019, 24, 272-278.	6.4	27
89	LOMETS2: improved meta-threading server for fold-recognition and structure-based function annotation for distant-homology proteins. Nucleic Acids Research, 2019, 47, W429-W436.	14.5	118
90	ERK Regulates HIF1α-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer. Clinical Cancer Research, 2019, 25, 5947-5960.	7.0	37

#	ARTICLE	IF	CITATIONS
91	An induced pluripotent stem cell line (TRNDi010-C) from a patient carrying a homozygous p.R401X mutation in the NGLY1 gene. Stem Cell Research, 2019, 39, 101496.	0.7	2
92	Deep‑learning contact‑map guided protein structure prediction in CASP13. Proteins: Structure, Function and Bioinformatics, 2019, 87, 1149-1164.	2.6	180
93	Detecting distant-homology protein structures by aligning deep neural-network based contact maps. PLoS Computational Biology, 2019, 15, e1007411.	3.2	45
94	455 – Differential Post-Translational Modification of Polymorphic Msh3 and Novel Binding Partner Nemo is Associated with Its Nuclear-To-Cytosol Shuttling. Gastroenterology, 2019, 156, S-96.	1.3	0
95	Lung Mammary Metastases but Not Primary Tumors Induce Accumulation of Atypical Large Platelets and Their Chemokine Expression. Cell Reports, 2019, 29, 1747-1755.e4.	6.4	11
96	Improving therapy of severe infections through drug repurposing of synergistic combinations. Current Opinion in Pharmacology, 2019, 48, 92-98.	3.5	51
97	Induced pluripotent stem cells for neural drug discovery. Drug Discovery Today, 2019, 24, 992-999.	6.4	63
98	α-Tocopherol Effect on Endocytosis and Its Combination with Enzyme Replacement Therapy for Lysosomal Disorders: A New Type of Drug Interaction?. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 823-833.	2.5	6
99	Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids. Drug Discovery Today, 2019, 24, 2126-2138.	6.4	15
100	An induced pluripotent stem cell line (TRNDi009-C) from a Niemann-Pick disease type A patient carrying a heterozygous p.L302P (c.905 T>C) mutation in the SMPD1 gene. Stem Cell Research, 2019, 38, 101461.	0.7	10
101	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA. Journal of Medicinal Chemistry, 2019, 62, 6175-6189.	6.4	26
102	Generation of an induced pluripotent stem cell line (TRNDi008-A) from a Hunter syndrome patient carrying a hemizygous 208insC mutation in the IDS gene. Stem Cell Research, 2019, 37, 101451.	0.7	5
103	17-Hydroxy Wortmannin Restores TRAIL's Response by Ameliorating Increased Beclin 1 Level and Autophagy Function in TRAIL-Resistant Colon Cancer Cells. Molecular Cancer Therapeutics, 2019, 18, 1265-1277.	4.1	6
104	Generation of an induced pluripotent stem cell line (TRNDi004-I) from a Niemann-Pick disease type B patient carrying a heterozygous mutation of p.L43_A44delLA in the SMPD1 gene. Stem Cell Research, 2019, 37, 101436.	0.7	3
105	I-TASSER gateway: A protein structure and function prediction server powered by XSEDE. Future Generation Computer Systems, 2019, 99, 73-85.	7.5	80
106	A human induced pluripotent stem cell line (TRNDi007-B) from an infantile onset Pompe patient carrying p.R854X mutation in the GAA gene. Stem Cell Research, 2019, 37, 101435.	0.7	9
107	High-Throughput Zika Viral Titer Assay for Rapid Screening of Antiviral Drugs. Assay and Drug Development Technologies, 2019, 17, 128-139.	1.2	8
108	An induced pluripotent stem cell line (TRNDi006-A) from a MPS IIIB patient carrying homozygous mutation of p.Glu153Lys in the NAGLU gene. Stem Cell Research, 2019, 37, 101427.	0.7	4

#	ARTICLE	IF	CITATIONS
109	Identification, design and synthesis of novel pyrazolopyridine influenza virus nonstructural protein 1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1113-1119.	2.2	14
110	Towards understanding bugs in an open source cloud management stack: An empirical study of OpenStack software bugs. Journal of Systems and Software, 2019, 151, 210-223.	4.5	12
111	Generation of an induced pluripotent stem cell line (TRNDi005-A) from a Mucopolysaccharidosis Type IVA (MPS IVA) patient carrying compound heterozygous p.R61W and p.WT405del mutations in the GALNS gene. Stem Cell Research, 2019, 36, 101408.	0.7	5
112	Phosphocyclocreatine is the dominant form of cyclocreatine in control and creatine transporter deficiency patient fibroblasts. Pharmacology Research and Perspectives, 2019, 7, e00525.	2.4	5
113	Cryo-EM structure of the human MLL1 core complex bound to the nucleosome. Nature Communications, 2019, 10, 5540.	12.8	47
114	Quantitative Chemotherapeutic Profiling of Gynecologic Cancer Cell Lines Using Approved Drugs and Bioactive Compounds. Translational Oncology, 2019, 12, 441-452.	3.7	14
115	Generation of an induced pluripotent stem cell line (TRNDi003-A) from a Noonan syndrome with multiple lentigines (NSML) patient carrying a p.Q510P mutation in the PTPN11 gene. Stem Cell Research, 2019, 34, 101374.	0.7	10
116	Generation of an induced pluripotent stem cell line (TRNDi002-B) from a patient carrying compound heterozygous p.Q208X and p.G310G mutations in the NGLY1 gene. Stem Cell Research, 2019, 34, 101362.	0.7	7
117	MetaGO: Predicting Gene Ontology of Non-homologous Proteins Through Low-Resolution Protein Structure Prediction and Protein–Protein Network Mapping. Journal of Molecular Biology, 2018, 430, 2256-2265.	4.2	58
118	Systemic Medication Associations with Presumed Advanced or Uncontrolled Primary Open-Angle Glaucoma. Ophthalmology, 2018, 125, 984-993.	5.2	56
119	Astrocytes as targets for drug discovery. Drug Discovery Today, 2018, 23, 673-680.	6.4	43
120	Neural stem cells for disease modeling and evaluation of therapeutics for infantile (CLN1/PPT1) and late infantile (CLN2/TPP1) neuronal ceroid lipofuscinoses. Orphanet Journal of Rare Diseases, 2018, 13, 54.	2.7	31
121	DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer. Cancer Letters, 2018, 428, 104-116.	7.2	60
122	Drug repurposing screens and synergistic drug–combinations for infectious diseases. British Journal of Pharmacology, 2018, 175, 181-191.	5.4	181
123	Repurposing a novel parathyroid hormone analogue to treat hypoparathyroidism. British Journal of Pharmacology, 2018, 175, 262-271.	5.4	15
124	Quantitative high–throughput screening identifies cytoprotective molecules that enhance SUMO conjugation *via* the inhibition of SUMO–specific protease (SENP)2. FASEB Journal, 2018, 32, 1677-1691.	0.5	29
125	Canvass: A Crowd-Sourced, Natural-Product Screening Library for Exploring Biological Space. ACS Central Science, 2018, 4, 1727-1741.	11.3	32
126	"Real-Time"High-Throughput Drug and Synergy Testing for Multidrug-Resistant Bacterial Infection: A Case Report. Frontiers in Medicine, 2018, 5, 267.	2.6	4

#	ARTICLE	IF	CITATIONS
127	Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease. Orphanet Journal of Rare Diseases, 2018, 13, 152.	2.7	34
128	Memory-Enhanced Dynamic Multi-Objective Evolutionary Algorithm Based on Lp Decomposition. Applied Sciences (Switzerland), 2018, 8, 1673.	2.5	23
129	Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3356-3362.	2.2	19
130	Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. Science Translational Medicine, 2018, 10, .	12.4	55
131	Optimization of the first small-molecule relaxin/insulin-like family peptide receptor (RXFP1) agonists: Activation results in an antifibrotic gene expression profile. European Journal of Medicinal Chemistry, 2018, 156, 79-92.	5.5	9
132	A Novel Method for Drug Screen to Regulate G Protein-Coupled Receptors in the Metabolic Network of Alzheimerâ€™s Disease. BioMed Research International, 2018, 2018, 1-10.	1.9	2
133	Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells. Translational Oncology, 2018, 11, 1053-1064.	3.7	8
134	Patient iPSC-derived neural stem cells exhibit phenotypes in concordance with the clinical severity of mucopolysaccharidosis I. Human Molecular Genetics, 2018, 27, 3612-3626.	2.9	23
135	Pluripotent Stem Cell Platforms for Drug Discovery. Trends in Molecular Medicine, 2018, 24, 805-820.	6.7	33
136	Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. Cell Discovery, 2018, 4, 31.	6.7	128
137	Repurposing Screen Identifies Unconventional Drugs With Activity Against Multidrug Resistant Acinetobacter baumannii. Frontiers in Cellular and Infection Microbiology, 2018, 8, 438.	3.9	37
138	Zika Virus: Origins, Pathological Action, and Treatment Strategies. Frontiers in Microbiology, 2018, 9, 3252.	3.5	58
139	Drugging SUMOylation for neuroprotection and oncotherapy. Neural Regeneration Research, 2018, 13, 415.	3.0	9
140	Methyl-Î²-cyclodextrin restores impaired autophagy flux in Niemann-Pick C1-deficient cells through activation of AMPK. Autophagy, 2017, 13, 1435-1451.	9.1	73
141	Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. Journal of Medicinal Chemistry, 2017, 60, 6364-6383.	6.4	12
142	PrAS: Prediction of amidation sites using multiple feature extraction. Computational Biology and Chemistry, 2017, 66, 57-62.	2.3	6
143	BindProfX: Assessing Mutation-Induced Binding Affinity Change by Protein Interface Profiles with Pseudo-Counts. Journal of Molecular Biology, 2017, 429, 426-434.	4.2	107
144	What DKKtates where to metastasize. Nature Cell Biology, 2017, 19, 1146-1148.	10.3	1

#	Article	IF	Citations
145	Efficient Synthesis of 1,9-Substituted Benzo[*h*][1,6]naphthyridin-2(1*H*)-ones and Evaluation of their *Plasmodium falciparum* Gametocytocidal Activities. ACS Combinatorial Science, 2017, 19, 748-754.	3.8	7
146	Identification of 4-phenylquinolin-2(1H)-one as a specific allosteric inhibitor of Akt. Scientific Reports, 2017, 7, 11673.	3.3	5
147	Drug discovery and development for rare genetic disorders. American Journal of Medical Genetics, Part A, 2017, 173, 2307-2322.	1.2	64
148	Neural stem cells for disease modeling of Wolman disease and evaluation of therapeutics. Orphanet Journal of Rare Diseases, 2017, 12, 120.	2.7	18
149	Synergistic drug combination effectively blocks Ebola virus infection. Antiviral Research, 2017, 137, 165-172.	4.1	75
150	An Improved MOEA/D with Optimal DE Schemes for Many-Objective Optimization Problems. Algorithms, 2017, 10, 86.	2.1	3
151	Treatment Paradigms for Retinal and Macular Diseases Using 3-D Retina Cultures Derived From Human Reporter Pluripotent Stem Cell Lines. , 2016, 57, ORSFl1.		35
152	gDNA-Prot: Predict DNA-binding proteins by employing support vector machine and a novel numerical characterization of protein sequence. Journal of Theoretical Biology, 2016, 406, 8-16.	1.7	13
153	A High-Throughput, Multi-Cell Phenotype Assay for the Identification of Novel Inhibitors of Chemotaxis/Migration. Scientific Reports, 2016, 6, 22273.	3.3	15
154	Drug combination therapy increases successful drug repositioning. Drug Discovery Today, 2016, 21, 1189-1195.	6.4	284
155	High-Throughput Phenotypic Screening of Human Astrocytes to Identify Compounds That Protect Against Oxidative Stress. Stem Cells Translational Medicine, 2016, 5, 613-627.	3.3	31
156	In vitro evaluation of imidazo[4,5 -c]quinolin-2-ones as gametocytocidal antimalarial agents. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2907-2911.	2.2	10
157	Induced Pluripotent Stem Cells for Disease Modeling and Evaluation of Therapeutics for Niemann-Pick Disease Type A. Stem Cells Translational Medicine, 2016, 5, 1644-1655.	3.3	29
158	Disease models for the development of therapies for lysosomal storage diseases. Annals of the New York Academy of Sciences, 2016, 1371, 15-29.	3.8	34
159	Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nature Medicine, 2016, 22, 1101-1107.	30.7	581
160	Molecular signatures associated with ZIKV exposure in human cortical neural progenitors. Nucleic Acids Research, 2016, 44, 8610-8620.	14.5	155
161	A New Glucocerebrosidase Chaperone Reduces Â-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. Journal of Neuroscience, 2016, 36, 7441-7452.	3.6	189
162	Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria. Emerging Microbes and Infections, 2016, 5, 1-11.	6.5	59

#	Article	IF	Citations
163	Inhibiting macrophage PI3KÎ³ to enhance immunotherapy. Cell Research, 2016, 26, 1267-1268.	12.0	21
164	Identification of Multiple Cryptococcal Fungicidal Drug Targets by Combined Gene Dosing and Drug Affinity Responsive Target Stability Screening. MBio, 2016, 7, .	4.1	19
165	High throughput cell-based assay for identification of glycolate oxidase inhibitors as a potential treatment for Primary Hyperoxaluria Type 1. Scientific Reports, 2016, 6, 34060.	3.3	20
166	A large-scale comparative assessment of methods for residueâ€"residue contact prediction. Briefings in Bioinformatics, 2016, 19, bbw106.	6.5	23
167	A novel quantitative high-throughput screen identifies drugs that both activate SUMO conjugation via the inhibition of microRNAs 182 and 183 and facilitate neuroprotection in a model of oxygen and glucose deprivation. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 426-441.	4.3	34
168	Multi-objective optimisation for regression testing. Information Sciences, 2016, 334-335, 1-16.	6.9	33
169	Maduramicin Rapidly Eliminates Malaria Parasites and Potentiates the Gametocytocidal Activity of the Pyrazoleamide PA21A050. Antimicrobial Agents and Chemotherapy, 2016, 60, 1492-1499.	3.2	23
170	Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. Journal of Medicinal Chemistry, 2016, 59, 841-853.	6.4	30
171	ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice. JCI Insight, 2016, 1, e88427.	5.0	16
172	Improved Species-Specific Lysine Acetylation Site Prediction Based on a Large Variety of Features Set. PLoS ONE, 2016, 11, e0155370.	2.5	26
173	Elabela-Apelin Receptor Signaling Pathway is Functional in Mammalian Systems. Scientific Reports, 2015, 5, 8170.	3.3	156
174	<scp>VEGF</scp> â€C is required for intestinal lymphatic vessel maintenance and lipid absorption. EMBO Molecular Medicine, 2015, 7, 1418-1425.	6.9	179
175	A cost-effective and efficient reprogramming platform for large-scale production of integration-free human induced pluripotent stem cells in chemically defined culture. Scientific Reports, 2015, 5, 11319.	3.3	96
176	Novel Numerical Characterization of Protein Sequences Based on Individual Amino Acid and Its Application. BioMed Research International, 2015, 2015, 1-8.	1.9	6
177	Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia. Cancer Cell, 2015, 27, 864-876.	16.8	265
178	High-Throughput Screening to Identify Compounds That Increase Fragile X Mental Retardation Protein Expression in Neural Stem Cells Differentiated From Fragile X Syndrome Patient-Derived Induced Pluripotent Stem Cells. Stem Cells Translational Medicine, 2015, 4, 800-808.	3.3	70
179	Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. Breast Cancer Research, 2015, 17, 59.	5.0	61
180	ERK and Î²-Arrestin Interaction: A Converging Point of Signaling Pathways for Multiple Types of Cell Surface Receptors. Journal of Biomolecular Screening, 2015, 20, 341-349.	2.6	29

#	Article	IF	Citations
181	High-Throughput Viability Assay Using an Autonomously Bioluminescent Cell Line with a Bacterial Lux Reporter. Journal of the Association for Laboratory Automation, 2015, 20, 164-174.	2.8	21
182	Genome-wide interaction analysis of quantitative traits in outbred mice. Genetical Research, 2015, 97, e9.	0.9	1
183	Endothelial Bmx tyrosine kinase activity is essential for myocardial hypertrophy and remodeling. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13063-13068.	7.1	31
184	Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay. Antiviral Research, 2015, 124, 20-29.	4.1	9
185	High-Throughput Screening, Discovery, and Optimization To Develop a Benzofuran Class of Hepatitis C Virus Inhibitors. ACS Combinatorial Science, 2015, 17, 641-652.	3.8	23
186	Analysis of Conformational B-Cell Epitopes in the Antibody-Antigen Complex Using the Depth Function and the Convex Hull. PLoS ONE, 2015, 10, e0134835.	2.5	20
187	Structural Basis for Inactivation of Giardia lamblia Carbamate Kinase by Disulfiram. Journal of Biological Chemistry, 2014, 289, 10502-10509.	3.4	51
188	Niemann–Pick Disease Type C: Induced Pluripotent Stem Cell–Derived Neuronal Cells for Modeling Neural Disease and Evaluating Drug Efficacy. Journal of Biomolecular Screening, 2014, 19, 1164-1173.	2.6	73
189	Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerging Microbes and Infections, 2014, 3, 1-7.	6.5	200
190	Macrophage Models of Gaucher Disease for Evaluating Disease Pathogenesis and Candidate Drugs. Science Translational Medicine, 2014, 6, 240ra73.	12.4	94
191	Divergence in a master variator generates distinct phenotypes and transcriptional responses. Genes and Development, 2014, 28, 409-421.	5.9	19
192	A Phenotypic Compound Screening Assay for Lysosomal Storage Diseases. Journal of Biomolecular Screening, 2014, 19, 168-175.	2.6	51
193	High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell lines. Human Molecular Genetics, 2014, 23, 1551-1562.	2.9	69
194	Quad-PRE: A Hybrid Method to Predict Protein Quaternary Structure Attributes. Computational and Mathematical Methods in Medicine, 2014, 2014, 1-9.	1.3	3
195	Angiopoietin 2 regulates the transformation and integrity of lymphatic endothelial cell junctions. Genes and Development, 2014, 28, 1592-1603.	5.9	115
196	An ensemble method for prediction of conformational B-cell epitopes from antigen sequences. Computational Biology and Chemistry, 2014, 49, 51-58.	2.3	21
197	Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects. Nucleic Acids Research, 2014, 42, 6591-6602.	14.5	46
198	newDNA-Prot: Prediction of DNA-binding proteins by employing support vector machine and a comprehensive sequence representation. Computational Biology and Chemistry, 2014, 52, 51-59.	2.3	20

#	Article	IF	Citations
199	Discovery, Optimization, and Characterization of Novel D_2 Dopamine Receptor Selective Antagonists. Journal of Medicinal Chemistry, 2014, 57, 3450-3463.	6.4	27
200	Discovery of Novel Antigiardiasis Drug Candidates. Antimicrobial Agents and Chemotherapy, 2014, 58, 7303-7311.	3.2	33
201	A High-Throughput Screening Assay for Fungicidal Compounds against Cryptococcus neoformans. Journal of Biomolecular Screening, 2014, 19, 270-277.	2.6	27
202	Novel Cell-Based Hepatitis C Virus Infection Assay for Quantitative High-Throughput Screening of Anti-Hepatitis C Virus Compounds. Antimicrobial Agents and Chemotherapy, 2014, 58, 995-1004.	3.2	30
203	Inhibition of HERG potassium channels by domiphen bromide and didecyl dimethylammonium bromide. European Journal of Pharmacology, 2014, 737, 202-209.	3.5	5
204	Chemical signatures and new drug targets for gametocytocidal drug development. Scientific Reports, 2014, 4, 3743.	3.3	89
205	Lymphangiogenic factors, mechanisms, and applications. Journal of Clinical Investigation, 2014, 124, 878-887.	8.2	257
206	A High Throughput Screening Assay System for the Identification of Small Molecule Inhibitors of gsp. PLoS ONE, 2014, 9, e90766.	2.5	16
207	Collaborative Development of 2-Hydroxypropyl-β-Cyclodextrin for the Treatment of Niemann-Pick Type C1 Disease. Current Topics in Medicinal Chemistry, 2014, 14, 330-339.	2.1	108
208	A high-throughput screening assay for assessing the viability of Cryptococcus neoformans under nutrient starvation conditions. Analytical and Bioanalytical Chemistry, 2013, 405, 6823-6829.	3.7	8
209	Phenotypic screens as a renewed approach for drug discovery. Drug Discovery Today, 2013, 18, 1067-1073.	6.4	363
210	Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nature Communications, 2013, 4, 2044.	12.8	76
211	Identification and optimization of small-molecule agonists of the human relaxin hormone receptor RXFP1. Nature Communications, 2013, 4, 1953.	12.8	54
212	Structure–Activity Relationship of Imidazopyridinium Analogues as Antagonists of Neuropeptide S Receptor. Journal of Medicinal Chemistry, 2013, 56, 9045-9056.	6.4	18
213	A quantitative high throughput assay for identifying gametocytocidal compounds. Molecular and Biochemical Parasitology, 2013, 188, 20-25.	1.1	45
214	Mechanism of HERG potassium channel inhibition by tetra-n-octylammonium bromide and benzethonium chloride. Toxicology and Applied Pharmacology, 2013, 267, 155-166.	2.8	14
215	A Novel Brain Penetrant NPS Receptor Antagonist, NCGC00185684, Blocks Alcohol-Induced ERK-Phosphorylation in the Central Amygdala and Decreases Operant Alcohol Self-Administration in Rats. Journal of Neuroscience, 2013, 33, 10132-10142.	3.6	27
216	Identification of Small-Molecule Agonists of Human Relaxin Family Receptor 1 (RXFP1) by Using a Homogenous Cell-Based cAMP Assay. Journal of Biomolecular Screening, 2013, 18, 670-677.	2.6	27

#	Article	IF	Citations
217	Statistical Analysis Reveals Co-Expression Patterns of Many Pairs of Genes in Yeast Are Jointly Regulated by Interacting Loci. PLoS Genetics, 2013, 9, e1003414.	3.5	17
218	An Alternative Direct Compound Dispensing Method Using the HP D300 Digital Dispenser. Journal of the Association for Laboratory Automation, 2013, 18, 367-374.	2.8	22
219	Identification of a Selective Small-Molecule Inhibitor Series Targeting the Eyes Absent 2 (Eya2) Phosphatase Activity. Journal of Biomolecular Screening, 2013, 18, 85-96.	2.6	33
220	Rapid Identification of Antifungal Compounds against Exserohilum rostratum Using High Throughput Drug Repurposing Screens. PLoS ONE, 2013, 8, e70506.	2.5	23
221	Evaluation of Cholesterol Reduction Activity of Methyl-β-cyclodextrin Using Differentiated Human Neurons and Astrocytes. Journal of Biomolecular Screening, 2012, 17, 1243-1251.	2.6	20
222	Deletion of the Endothelial Bmx Tyrosine Kinase Decreases Tumor Angiogenesis and Growth. Cancer Research, 2012, 72, 3512-3521.	0.9	31
223	γ-Tocopherol Reduces Lipid Accumulation in Niemann-Pick Type C1 and Wolman Cholesterol Storage Disorders. Journal of Biological Chemistry, 2012, 287, 39349-39360.	3.4	107
224	Plasma and Tissue Concentrations of α-Tocopherol and γ-Tocopherol Following High Dose Dietary Supplementation in Mice. Nutrients, 2012, 4, 467-490.	4.1	20
225	Non-iminosugar glucocerebrosidase small molecule chaperones. MedChemComm, 2012, 3, 56-60.	3.4	22
226	Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1–CBFβ interaction. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 14592-14597.	7.1	108
227	Discovery of a Novel Noniminosugar Acid α Glucosidase Chaperone Series. Journal of Medicinal Chemistry, 2012, 55, 7546-7559.	6.4	27
228	Discovery, Structure–Activity Relationship, and Biological Evaluation of Noninhibitory Small Molecule Chaperones of Glucocerebrosidase. Journal of Medicinal Chemistry, 2012, 55, 5734-5748.	6.4	113
229	A high-throughput sphingomyelinase assay using natural substrate. Analytical and Bioanalytical Chemistry, 2012, 404, 407-414.	3.7	7
230	A high throughput glucocerebrosidase assay using the natural substrate glucosylceramide. Analytical and Bioanalytical Chemistry, 2012, 402, 731-739.	3.7	31
231	Two high-throughput screening assays for aberrant RNA–protein interactions in myotonic dystrophy type 1. Analytical and Bioanalytical Chemistry, 2012, 402, 1889-1898.	3.7	49
232	High Throughput Screening for Small Molecule Therapy for Gaucher Disease Using Patient Tissue as the Source of Mutant Glucocerebrosidase. PLoS ONE, 2012, 7, e29861.	2.5	62
233	High-Throughput Multiplexed Quantitation of Protein Aggregation and Cytotoxicity in a Huntington's Disease Model. Current Chemical Genomics, 2012, 6, 79-86.	2.0	22
234	A Homogenous Luminescence Assay Reveals Novel Inhibitors for Giardia LambliaCarbamate Kinase. Current Chemical Genomics, 2012, 6, 93-102.	2.0	16

#	Article	IF	Citations
235	The synthesis and evaluation of dihydroquinazolin-4-ones and quinazolin-4-ones as thyroid stimulating hormone receptor agonists. MedChemComm, 2011, 2, 1016.	3.4	9
236	Discovery, Synthesis, and Biological Evaluation of Novel SMN Protein Modulators. Journal of Medicinal Chemistry, 2011, 54, 6215-6233.	6.4	38
237	Evaluation of Quinazoline Analogues as Glucocerebrosidase Inhibitors with Chaperone Activity. Journal of Medicinal Chemistry, 2011, 54, 1033-1058.	6.4	59
238	VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. Nature Cell Biology, 2011, 13, 1202-1213.	10.3	272
239	Novel Patient Cell-Based HTS Assay for Identification of Small Molecules for a Lysosomal Storage Disease. PLoS ONE, 2011, 6, e29504.	2.5	11
240	Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels. Toxicology and Applied Pharmacology, 2011, 252, 250-258.	2.8	34
241	Phosphodiesterase 4 inhibitors enhance sexual pleasure-seeking activity in rodents. Pharmacology Biochemistry and Behavior, 2011, 98, 349-355.	2.9	2
242	Notch restricts lymphatic vessel sprouting induced by vascular endothelial growth factor. Blood, 2011, 118, 1154-1162.	1.4	116
243	High-Throughput *Giardia lamblia* Viability Assay Using Bioluminescent ATP Content Measurements. Antimicrobial Agents and Chemotherapy, 2011, 55, 667-675.	3.2	43
244	Role of synectin in lymphatic development in zebrafish and frogs. Blood, 2010, 116, 3356-3366.	1.4	36
245	Effective Suppression of Vascular Network Formation by Combination of Antibodies Blocking VEGFR Ligand Binding and Receptor Dimerization. Cancer Cell, 2010, 18, 630-640.	16.8	119
246	Evaluation of 2-thioxo-2,3,5,6,7,8-hexahydropyrimido[4,5-d]pyrimidin-4(1H)-one analogues as GAA activators. European Journal of Medicinal Chemistry, 2010, 45, 1880-1897.	5.5	24
247	Fabry Disease – Current Treatment and New Drug Development. Current Chemical Genomics, 2010, 4, 50-56.	2.0	42
248	High Throughput Screening for Inhibitors of Alpha-Galactosidase. Current Chemical Genomics, 2010, 4, 67-73.	2.0	16
249	Selective Modulation of Gq/Gs pathways by Naphtho Pyrano Pyrimidines As Antagonists of the Neuropeptide S Receptor. ACS Chemical Neuroscience, 2010, 1, 559-574.	3.5	25
250	A Multiplex Calcium Assay for Identification of GPCR Agonists and Antagonists. Assay and Drug Development Technologies, 2010, 8, 362-374.	1.2	29
251	Small Molecule Drug Discovery for Fabry Disease. , 2010, , 163-177.		0
252	The Pilot Phase of the NIH Chemical Genomics Center. Current Topics in Medicinal Chemistry, 2009, 9, 1181-1193.	2.1	28

#	Article	IF	Citations
253	An AlphaScreenâ„¢-Based High-Throughput Screen to Identify Inhibitors of Hsp90-Cochaperone Interaction. Journal of Biomolecular Screening, 2009, 14, 273-281.	2.6	47
254	Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12471-12476.	7.1	102
255	Cardiac Glycosides Inhibit p53 Synthesis by a Mechanism Relieved by Src or MAPK Inhibition. Cancer Research, 2009, 69, 6556-6564.	0.9	105
256	Automated High-Content Screening for Compounds That Disassemble the Perinucleolar Compartment. Journal of Biomolecular Screening, 2009, 14, 1045-1053.	2.6	25
257	Synthesis and characterization of a new fluorogenic substrate for alpha-galactosidase. Analytical and Bioanalytical Chemistry, 2009, 394, 1903-1909.	3.7	11
258	Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death. Bioorganic and Medicinal Chemistry, 2009, 17, 5139-5145.	3.0	33
259	A new resorufin-based Î±-glucosidase assay for high-throughput screening. Analytical Biochemistry, 2009, 390, 79-84.	2.4	23
260	A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel. Analytical Biochemistry, 2009, 394, 30-38.	2.4	62
261	Multi-Gram Scale Synthesis of FR180204. Journal of Organic Chemistry, 2009, 74, 8870-8873.	3.2	22
262	A Robotic Platform for Quantitative High-Throughput Screening. Assay and Drug Development Technologies, 2008, 6, 637-657.	1.2	126
263	Quantitative High-Throughput Screening Using a Live-Cell cAMP Assay Identifies Small-Molecule Agonists of the TSH Receptor. Journal of Biomolecular Screening, 2008, 13, 120-127.	2.6	59
264	A Cell-Based PDE4 Assay in 1536-Well Plate Format for High-Throughput Screening. Journal of Biomolecular Screening, 2008, 13, 609-618.	2.6	21
265	Compound Management for Quantitative High-Throughput Screening. Journal of the Association for Laboratory Automation, 2008, 13, 79-89.	2.8	72
266	A Miniaturized Glucocorticoid Receptor Translocation Assay Using Enzymatic Fragment Complementation Evaluated with qHTS. Combinatorial Chemistry and High Throughput Screening, 2008, 11, 545-559.	1.1	15
267	Optimization and Validation of Two Miniaturized Glucocerebrosidase Enzyme Assays for High Throughput Screening. Combinatorial Chemistry and High Throughput Screening, 2008, 11, 817-824.	1.1	35
268	EDITORIAL. Current Chemical Genomics, 2008, 1, 1-1.	2.0	1
269	Comparison on Functional Assays for Gq-Coupled GPCRs by Measuring Inositol Monophospate-1 and Intracellular Calcium in 1536-Well Plate Format. Current Chemical Genomics, 2008, 1, 70-78.	2.0	32
270	Evaluation of Micro-Parallel Liquid Chromatography as a Method for HTS-Coupled Actives Verification. Assay and Drug Development Technologies, 2007, 5, 815-824.	1.2	4

#	Article	IF	Citations
271	Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13192-13197.	7.1	139
272	N4-Phenyl modifications of N2-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5783-5789.	2.2	30
273	High-throughput screening assays for the identification of chemical probes. Nature Chemical Biology, 2007, 3, 466-479.	8.0	555
274	Fluorescent Protein‐Based Cellular Assays Analyzed by Laser‐Scanning Microplate Cytometry in 1536‐Well Plate Format. Methods in Enzymology, 2006, 414, 566-589.	1.0	29
275	Identification of small molecule antagonists of the human mas-related gene-X1 receptor. Analytical Biochemistry, 2006, 351, 50-61.	2.4	30
276	A Cell-Based Ultra-High-Throughput Screening Assay for Identifying Inhibitors of D-Amino Acid Oxidase. Journal of Biomolecular Screening, 2006, 11, 481-487.	2.6	54
277	Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical libraries. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 11473-11478.	7.1	733
278	High-Throughput Screening of 11β-Hydroxysteroid Dehydrogenase Type 1 in Scintillation Proximity Assay Format. Assay and Drug Development Technologies, 2005, 3, 377-384.	1.2	11
279	A Short-Incubation Reporter-Gene Assay for High-Throughput Screening of Estrogen Receptor-α Antagonists. Assay and Drug Development Technologies, 2005, 3, 393-400.	1.2	5
280	Application of Division Arrest Technology to Cell-Based HTS: Comparison with Frozen and Fresh Cells. Assay and Drug Development Technologies, 2005, 3, 17-26.	1.2	36
281	A 1,536-Well cAMP Assay for Gs- and Gi-Coupled Receptors Using Enzyme Fragmentation Complementation. Assay and Drug Development Technologies, 2004, 2, 39-49.	1.2	30
282	High-Throughput Cell-Based Screening Using Scintillation Proximity Assay for the Discovery of Inositol Phosphatase Inhibitors. Journal of Biomolecular Screening, 2004, 9, 132-140.	2.6	10
283	High Throughput Assay Technologies for Ion Channel Drug Discovery. Assay and Drug Development Technologies, 2004, 2, 543-552.	1.2	120
284	Application of Real-Time Cell Electronic Sensing (RT-CES) Technology to Cell-Based Assays. Assay and Drug Development Technologies, 2004, 2, 363-372.	1.2	343
285	Scintillation proximity assay of inositol phosphates in cell extracts: High-throughput measurement of G-protein-coupled receptor activation. Analytical Biochemistry, 2003, 313, 311-318.	2.4	82
286	2-Arylindole-3-acetamides. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 865-869.	2.2	17
287	Miniaturization of a Hepatitis C Virus RNA Polymerase Assay Using a $-102°C$ Cooled CCD Camera-Based Imaging System. Analytical Biochemistry, 2001, 290, 214-220.	2.4	26
288	Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor. Journal of Biological Chemistry, 1998, 273, 15687-15692.	3.4	123

#	Article	IF	Citations
289	Increased Expression of the Cardiac L-type Calcium Channel in Estrogen Receptor–deficient Mice. Journal of General Physiology, 1997, 110, 135-140.	1.9	165
290	Thermodynamic and kinetic aspects of agonist and antagonist binding to 1,4-dihydropyridine receptors. European Journal of Pharmacology, 1991, 208, 137-147.	2.6	6